Positive Phase III Builds Case for Intra-Cellular’s Depression Drug
Intra-Cellular Therapies’ Caplyta met its primary endpoint in the Phase III Study 403 trial, easing the burden of depressive episodes in patients with major depressive disorder or bipolar depression.
Positive Phase III Builds Case for Intra-Cellular’s Depression Drug Read More »
